Systemic Safety Concerns A case report documented a 39-year-old male who injected 6 mg of MT-2 (approximately 12x the standard starting dose) and developed rhabdomyolysis breakdown of muscle tissue that can cause kidney damage (Nelson et al., 2012)
The timeline for seeing results from peptide and NAD+ therapies can vary significantly based on individual factors, including the specific compounds used, the condition being treated, and the persons overall health
GIP (Glucose-dependent Insulinotropic Polypeptide) Receptor Agonist: Works synergistically with GLP-1 to improve lipid (fat) metabolism and further stabilize blood sugar levels
We also recently published that GLP-1s might reduce the incidence of cataracts, which we also speculate may be related to reduced ocular [eye] inflammation, said Young
doi: 10.3390/ijms24086936 324 WirtuSFRamaswamyKMaitraRChopraSMishraAKJuleLT
Unlike glutathione, acetyl glutathione is absorbed well orally